Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05377827
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:51.981219+00:00
Published At
2025-04-29T00:00:00+00:00
Record Updated At
2025-04-29
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["T-Cell Non-Hodgkin Lymphoma", "Acute Myeloid Leukemia", "Angioimmunoblastic T-cell Lymphoma", "Enteropathy-Associated T-Cell Lymphoma", "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma", "Peripheral T Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Adult T Cell Leukemia", "Adult T Cell Lymphoma", "T Cell Prolymphocytic Leukemia", "Extranodal NK/T-cell Lymphoma", "Transformed Mycosis Fungoides", "Sezary Syndrome", "Primary Cutaneous Gamma-Delta T-Cell Lymphoma", "Hepatosplenic T-cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-04-29"
protocolSection.identificationModule.nctId
"NCT05377827"
protocolSection.identificationModule.officialTitle
"Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • T-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Angioimmunoblastic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Enteropathy-Associated T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Peripheral T Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Adult T Cell Leukemia (protocolSection.conditionsModule.conditions)
  • Adult T Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • T Cell Prolymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Extranodal NK/T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Transformed Mycosis Fungoides (protocolSection.conditionsModule.conditions)
  • Sezary Syndrome (protocolSection.conditionsModule.conditions)
  • Primary Cutaneous Gamma-Delta T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Hepatosplenic T-cell Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.